Loading clinical trials...

A Longitudinal Observational Study of the Natural History and Management of Patients With HCC | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

A Longitudinal Observational Study of the Natural History and Management of Patients With Hepatocellular Carcinoma

NCT02954094•Target PharmaSolutions, Inc.

View on ClinicalTrials.gov

Summary

TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Male or female patients, age ≥18 years
•2. Patients with a histological/cytological or radiological diagnosis of HCC (mixed HCC cholangiocarcinoma may be included; patients who are candidates for surgical and non-surgical treatment, as well as those being followed without specific HCC therapy may be included)

Exclusion Criteria

•1\. Inability to provide written informed consent

Locations (71)

Banner University Medical Center

Phoenix, Arizona, United States

University of Arkansas

Little Rock, Arkansas, United States

University of Southern California/Norris Comprehensive Cancer Center

Los Angeles, California, United States

Stanford University

Palo Alto, California, United States

California Liver Research Institute

Pasadena, California, United States

University of California-Davis

Sacramento, California, United States

University of California

San Francisco, California, United States

Georgetown University

Washington D.C., District of Columbia, United States

Gastro Florida

Clearwater, Florida, United States

University of Florida Hepatology Research at CTRB

Gainesville, Florida, United States

Key Dates

Start Date

December 1, 2016

Primary Completion Date

February 1, 2026

Completion Date

February 1, 2027

Last Updated

February 6, 2026

Enrollment

10,000

ESTIMATED participants

Conditions

Hepatocellular Cancer

Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC

NCT04912765

Hepatocellular CarcinomaHepatocellular Cancer+3 more

View study

RECRUITINGPHASE2

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

NCT05451043

Pancreatic CancerHepatocellular Cancer+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 6, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

Inclusion Criteria

Exclusion Criteria

Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer

Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers